middle.news
Sichuan Study Validates TruScreen’s AI Edge in Cervical Cancer Screening
8:46am on Monday 9th of March, 2026 AEDT
•
Healthcare
Read Story
Sichuan Study Validates TruScreen’s AI Edge in Cervical Cancer Screening
8:46am on Monday 9th of March, 2026 AEDT
Key Points
297-patient peer-reviewed study shows TruScreen + hr-HPV superior to Thinprep cytology + hr-HPV
Higher sensitivity, specificity, and diagnostic accuracy for TruScreen in detecting cervical lesions
Supports TruScreen’s partnership with Dalton BioSciences for global HPV test distribution
Adds to over 30 clinical trials and 40,000 women screened validating TruScreen technology
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Truscreen (ASX:TRU)
OPEN ARTICLE